Staar Surgical (STAA) shares plummeted 37.39% in the pre-market session on Wednesday, following the company's disappointing fourth-quarter and full-year 2024 financial results, which were heavily impacted by weak demand and economic challenges in China, a critical market for its eye surgery products.
The company reported a net loss of $34.2 million, or $0.69 per share, for the fourth quarter, missing analyst estimates of a $0.16 loss per share. Net sales for the quarter were $48.95 million, significantly lower than the consensus estimate of $77.29 million.
The primary driver behind the weak performance was the challenges faced in China, where sales of Implantable Collamer Lenses (ICL) declined by 13% year-over-year to $161 million for fiscal 2024. Staar Surgical attributed this decline to fluctuating demand and weak consumer sentiment in China, which is expected to continue, especially in the first half of 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。